<DOC>
	<DOCNO>NCT01257178</DOCNO>
	<brief_summary>The purpose study evaluate impact hepatic dysfunction pharmacokinetics safety LY2624803 major metabolite , LSN2797276 .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics LY2624803 Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<criteria>All Subjects Sexually active male female subject partner must agree use 2 method contraception condom occlusive cap ( diaphragm cervical/vault cap ) together spermicidal foam/gel/film/cream/suppository , time subject enters study 3 month final dosing occasion , unless male subject partner sterilize ( confirm azoospermia ) . Have BMI 18.5 35.0 kg/m2 , inclusive . Have body weight &gt; 50 kg . Have normal sit blood pressure heart rate compatible disease state , determine investigator . Have venous access sufficient allow blood sample per protocol . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Lilly Ethical Review Board govern site . Control Subjects Are males female normal hepatic function , determine medical history physical examination . Have clinical laboratory test result within normal reference range investigator site , result minor deviation consider clinically significant investigator . Hepatic Impaired Subjects •Have stable hepatic impairment ( alcoholic , posthepatitis , biliary cirrhosis , cryptogenic ) classify ChildPugh class A , B , C ( mild , moderate , severe impairment ) consider acceptable participation study investigator . All Subjects Are currently enrol , discontinue within last 90 day last dosing occasion clinical trial involve investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study . Have know allergy LY2624803 relate compound . Have previously discontinue study study investigate LY2624803 . Have abnormality 12lead ECG , opinion investigator , increase risk associate participate study . Regularly use know drug abuse and/or show positive finding urinary drug screening . Show evidence human immunodeficiency virus ( HIV ) and/or positive HIV antibody . Have donate blood 500 mL within last 3 month prior screen visit . Use drug herbal remedy know inhibitor inducer CYP3A4 inhibitor CYP2D6 enzyme pathway , unless opinion sponsor investigator medication compromise safety . Are liver transplant subject take immunosuppressant follow organ transplant . Have show sign variceal bleed last 2 week prior screen . Show evidence irritable bowel syndrome chronic diarrhea . Have average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , subject unwilling stop alcohol consumption duration study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Are unable swallow whole capsule . Are total parenteral nutrition ( TPN ) . Take anticoagulant therapeutic use . Have history breast cancer . Exhibit condition , , opinion investigator would preclude participation study . Control Subjects Have medically significant history neurologic disease , cancer , cardiac , respiratory , metabolic , hepatic , renal , gastrointestinal ( except appendectomy ) , dermatological , venereal , hematological disorder disease . Have creatinine clearance ( CrCl ) &lt; 80 mL/min , calculate CockcroftGault equation . Show evidence significant active neuropsychiatric disease opinion investigator . Show evidence hepatitis B and/or positive hepatitis B surface antigen ( HBsAg ) . Show evidence hepatitis C and/or positive hepatitis C antibody . Mild Hepatic Impaired Subjects ( ChildPugh A ) Show evidence significant active disease responsible associate hepatic impairment . Show evidence active renal disease creatinine clearance &lt; 70 mL/min calculate CockcroftGault equation . Have severe ascites . Moderate Severe Hepatic Impaired Subjects ( ChildPugh B C ) Show evidence significant active disease responsible associate moderate severe hepatic impairment . Show evidence hepatorenal syndrome show creatinine clearance &lt; 50 mL/min , calculate CockcroftGault equation . Have show sign spontaneous bacterial peritonitis within 6 month prior dose . Have severe hyponatremia . Have hepatic encephalopathy ( grade 2 4 encephalopathy ) . Show sign hepatocellular carcinoma . Have portal shunt . Show , opinion investigator , evidence significant active neuropsychiatric disease grade 1 hepatic encephalopathy . Have severe ascites . Have hemoglobin concentration &lt; 9.0 g/dL . Have platelet count &lt; 50 x 109 cells/L , unless , consultation sponsor , consider acceptable participation study . Have total serum bilirubin concentration &gt; 15 mg/dL ( &gt; 257 µmol/L ) . Take medication know interfere hepatic metabolism ( example barbiturate , phenothiazine ) know alter major organ system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>